Genetically-encoded platforms direct kinase inhibitor drugs to organelles to reveal new dimensions of local kinase signaling.

Libraries of patient-derived tumor organoids are a reliable and scalable model system that can help identify and optimize targeted therapies in a pre-clinical setting.

The microRNA, miR-146a, is regulated by mutant BRAF/NRAS proteins, and promotes the development of melanoma via increasing Notch signaling pathway, suggesting that combining drugs targeting BRAF/NRAS and Notch may provide an effective melanoma treatment.

Drugs called bisphosphonates are used to treat a range of bone diseases, but how do they reach the enzymes that are their target?

Experimental efforts to validate the output of a computational model that predicts new uses for existing drugs highlights the inherently complex nature of cancer biology.

Editors' Summary: This Replication Study has reproduced important parts of the original paper.

The mode of binding and cellular effect of the first FOXO3-DNA-binding-domain targeting small compound discovered by a combined pharmacophore-based/biochemical screening approach is reported.

A drug used in hormone replacement therapy can target estrogen receptors that have become resistant to breast cancer treatments.